1-[6-(二甲基氨基)-3-吡啶基]乙酮 | 265107-41-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-[6-(二甲基氨基)-3-吡啶基]乙酮
• 英文名称: 1-(6-dimethylaminopyrid-3-yl)ethanone
• 英文别名: 1-(6-(dimethylamino)pyridin-3-yl)ethanone；1-[6-(Dimethylamino)-3-pyridinyl]ethanone；1-[6-(dimethylamino)pyridin-3-yl]ethanone
• CAS: 265107-41-3
• 化学式: C₉H₁₂N₂O
• 分子量: 164.207
• InChiKey: XALNIAGSHWLPDP-UHFFFAOYSA-N

物化性质

• 熔点：
  63.8-64.2 °C
• 沸点：
  309.7±27.0 °C(Predicted)
• 密度：
  1.078±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[6-(二甲基氨基)-3-吡啶基]乙酮 在 乙酸铵 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 5-(3-Bromo-phenyl)-7-(6-dimethylamino-pyridin-3-yl)-pyrido[2,3-d]pyrimidin-4-ylamine
  参考文献：
  名称：

  5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure–activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors

  摘要：

  4-Amino-5,7-disubstituted pyridopyrimidines are potent, non-nucleoside inhibitors of adenosine kinase (AK). We recently identified a potent, orally efficacious analog, 4 containing a 7-pyridylmorpholine substituted ring system as the key structural element of this template. In this report, we disclose the pharmacologic effects of five- and six-membered heterocyclic ring replacements for the pyridine ring in 4. These replacements were found to have interesting effects on in vivo efficacy and genotoxicity as well as in vitro potency. We discovered that the nitrogen in the heterocyclic ring at C(7) is important for the modulation of mutagenic side effects (Ames assay). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.03.023
• 作为产物：
  描述：

  6-氯吡啶-3-羰酰氯 在 三乙胺 、 magnesium chloride 作用下， 以 乙醇 、 水 、 二甲基亚砜 、 甲苯 为溶剂， 反应 3.33h， 生成 1-[6-(二甲基氨基)-3-吡啶基]乙酮
  参考文献：
  名称：

  5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure–activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors

  摘要：

  4-Amino-5,7-disubstituted pyridopyrimidines are potent, non-nucleoside inhibitors of adenosine kinase (AK). We recently identified a potent, orally efficacious analog, 4 containing a 7-pyridylmorpholine substituted ring system as the key structural element of this template. In this report, we disclose the pharmacologic effects of five- and six-membered heterocyclic ring replacements for the pyridine ring in 4. These replacements were found to have interesting effects on in vivo efficacy and genotoxicity as well as in vitro potency. We discovered that the nitrogen in the heterocyclic ring at C(7) is important for the modulation of mutagenic side effects (Ames assay). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.03.023

文献信息

• [EN] NOVEL COMPOUNDS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH THE AGGREGATION OF ALPHA-SYNUCLEIN<br/>[FR] NOUVEAUX COMPOSÉS POUR LE DIAGNOSTIC, LE TRAITEMENT ET LA PRÉVENTION DE MALADIES ASSOCIÉES À L'AGRÉGATION DE L'ALPHA-SYNUCLÉINE
  申请人：MODAG GMBH

  公开号：WO2021099518A1

  公开（公告）日：2021-05-27

  The present invention relates to compounds represented by general formula (la), (lb), (lla) or(llb). These compounds are suitable for imaging alpha-synuclein and for diagnosing diseases which are associated with the aggregation of alpha-synuclein. The compounds are also useful for treating and preventing diseases which are associated with the aggregation of alpha-synuclein.

  本发明涉及由通式(la)、(lb)、(lla)或(llb)表示的化合物。这些化合物适用于成像α-突触核蛋白和诊断与α-突触核蛋白聚集相关的疾病。这些化合物还适用于治疗和预防与α-突触核蛋白聚集相关的疾病。
• Pyrimidinone Derivatives as Antimalarial Agents
  申请人：SANOFI

  公开号：US20150183804A1

  公开（公告）日：2015-07-02

  The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n=0 or 1 and R 2 is a methyl group when n=0 and a hydrogen atom when n=1. Process for the preparation thereof and therapeutic use thereof.

  这项发明涉及一种新型的嘧啶酮基杂环化合物，这些化合物是寄生虫生长抑制剂，其一般式为（I），其中Y是从三种桥联吗啉中选择的吗啉，L是键或连接物，n=0或1，当n=0时R2是甲基基团，当n=1时是氢原子。其制备方法和治疗用途。
• [EN] DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] COMPOSÉS DE DIHYDROPYRIDINONE INHIBITEURS DE LA MGAT2 DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015134701A1

  公开（公告）日：2015-09-11

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

  本发明提供了以下式（I）的化合物：或其立体异构体，或其药学上可接受的盐，其中所有变量均如本文所定义。这些化合物是单酰基甘油酰基转移酶2（MGAT2）抑制剂，可用作药物。
• Acetylation of <i>N</i>-Heteroaryl Bromides via PdCl₂/(<i>o</i>-tolyl)₃P Catalyzed Heck Reactions
  作者：Xiaochun Tao、Lisheng Cai、Tianxiong He、Xinyan Wu、Victor Pike

  DOI：10.1055/s-2008-1032193

  日期：2008.3

  user-friendly and convenient method for the acetylation of N-heteroaryl bromides is described. This process is based on the palladium-catalyzed olefination of an N-heteroaryl bromide with butyl vinyl ether, followed by acid hydrolysis of the intermediate heteroaryl vinyl ether in situ. Isopropanol at 85 °C, in the presence of K 3 PO 4 ·3H 2 O (2 equiv), PdCl 2 (2 mol%) and ( O-tolyl) 3 P (4 mol%), provided

  描述了一种新的用户友好和方便的 N-杂芳基溴乙酰化方法。该方法基于钯催化的 N-杂芳基溴化物与丁基乙烯基醚的烯化反应，然后是中间体杂芳基乙烯基醚的原位酸水解。异丙醇在 85 °C，在 K 3 PO 4 ·3H 2 O (2 equiv)、PdCl 2 (2 mol%) 和 ( O-tolyl) 3 P (4 mol%) 存在下，提供了最佳条件，给出N-杂芳基溴的产率高达 75%。
• Thiazole derivatives
  申请人：Nakajima Takao

  公开号：US20070105919A1

  公开（公告）日：2007-05-10

  (Wherein n is an integer of from 0 to 3; R 1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R 2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, —COR 8 , or the like; R 3 and R 4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, —COR 12 , or the like) For example, provided are adenosine A 2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.

  其中n为0至3的整数；R1代表取代或未取代的环烷基、取代或未取代的芳基、取代或未取代的脂环杂环基或取代或未取代的芳香杂环基；R2代表卤素、取代或未取代的低碳基、取代或未取代的芳基、取代或未取代的脂环杂环基、取代或未取代的芳香杂环基、-COR8或类似物；R3和R4可以相同也可以不同，每个代表氢原子、取代或未取代的低碳基、取代或未取代的芳基烷基、-COR12或类似物。例如，提供了包含噻唑衍生物的腺苷A2A受体拮抗剂作为活性成分，其表示为通式（I）或其药学上可接受的盐等。